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Abstract 
Background Adiponectin is secreted by adipose tissue and may play a role in cardiovascular 
disease. We examined adiponectin levels in patients with type 2 diabetes who participated in the 
Telmisartan versus Ramipril in Renal Endothelial Dysfunction (TRENDY) study. 
Methods Eighty-seven patients were assessed at baseline and following 9 weeks treatment with the 
angiotensin-receptor blocker telmisartan (final dose, 80 mg; n=45) or the angiotensin-converting 
enzyme inhibitor ramipril (final dose, 10 mg; n=42). Adiponectin levels were measured in plasma 
by radioimmunoassay. 
Results Adiponectin levels were inversely correlated with systolic (SBP; r=-0.240, P<0.05) and 
diastolic (DBP; r=-0.227, P<0.05) blood pressure at baseline and following treatment with 
telmisartan or ramipril (SBP: r=-0.228, P<0.05; DBP: r=-0.286, P<0.05). Changes in adiponectin 
levels were related to changes in SBP (r=-0.357, P<0.01) and DBP (r=-0.286, P<0.01). There was a 
significant increase in adiponectin levels in the telmisartan (0.68 [95% CI, 0.27 to 1.10] µg/mL, 
P<0.01) but not in the ramipril group (0.17 [95% CI, -0.56 to 0.90] µg/mL, P=0.67). Blood pressure 
reduction in the telmisartan group (∆SBP: -13.5 [95% CI, -17.0 to -10.0] mmHg; ∆DBP: -7.6 [95% 
CI, -9.8 to -5.3] mmHg, each P<0.001) was significantly (P=<0.01 for systolic and P<0.01 for 
diastolic blood pressure) greater than in the ramipril group (∆SBP: -6.1 [95% CI, -6.2 to -2.0] 
mmHg; ∆DBP: -2.7 [95% CI, -5.0 to -0.5] mmHg; P<0.01 and P<0.05, respectively). 
Conclusion Adiponectin is correlated with blood pressure in patients with type 2 diabetes. Whether 
increased adiponectin contributes to the blood pressure-lowering effect of telmisartan needs further 
study. 
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Introduction 
Adiponectin is an adipose tissue-specific plasma protein. Plasma adiponectin levels are decreased in 
diabetes, metabolic syndrome and coronary artery disease [1-3]. Adiponectin increases insulin 
sensitivity [4] and stimulates endothelial nitric oxide production [5]. Reduced adiponectin levels 
therefore provide a link between insulin resistance and endothelial dysfunction in cardiovascular 
disease (for review see [6-8]). 
There is increasing evidence that adiponectin is also involved in the pathogenesis of hypertension. 
Plasma adiponectin levels have been found to be lower in hypertensive compared to normotensive 
subjects [9,10]. Hypoadiponectinemia independently predicts development of hypertension in a 
nondiabetic population cohort [10], and plasma adiponectin levels are inversely related to blood 
pressure in normotensive men [9]. An adiponectin-knockout mouse exhibits obesity, insulin 
resistance and hypertension when put on high-fat/high-sucrose/high-salt diet [11]. Similar findings 
have been described in obese KKAy mice that have low adiponectin levels [12]. Both mouse 
models respond with amelioration of hypertension to adenovirus-mediated adiponectin 
replenishment [12]. Potential pathomechanisms include action of adiponectin on endothelial 
function, sympathetic nervous system and the renin-angiotensin-aldosterone system [13]. 
Angiotensin receptor blockers (ARBs) and particularly the ARBs telmisartan and irbesartan have 
been shown to increase plasma adiponectin levels by inducing peroxisome proliferator-activated 
receptor-γ (PPARγ) activity independent of their AT1-receptor blocking actions [14,15]. 
Telmisartan stimulates adiponectin protein expression in adipocytes and preadipocytes via PPARγ 
activation although the exact mechanisms remain unclear [16-18]. PPARγ-independent stimulation 
of adiponectin by telmisartan has also been reported [19]. 
We hypothesised that the blood pressure-lowering effect of telmisartan is related to its potential to 
increase adiponectin levels. To test our hypothesis we retrospectively analysed data from the 
Telmisartan versus Ramipril in Renal Endothelial Dysfunction (TRENDY) study [20]. In 
TRENDY, patients with type 2 diabetes and hypertension, who will particularly benefit from blood 
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pressure reduction and increase in adiponectin levels, were treated with the ARB telmisartan and 
the angiotensin-converting enzyme (ACE) inhibitor ramipril. 
 
Methods 
Patients 
Details of study design, inclusion and exclusion criteria have been published previously [20]. In 
brief, patients with type 2 diabetes and hypertension were included if systolic blood pressure (SBP) 
was 140-179 mmHg and/or diastolic blood pressure (DBP) was 90-109 mmHg if untreated, or SBP 
<180 mmHg and/or DBP <110 mmHg if on antihypertensive medication. Exclusion criteria 
included poor diabetes control (glycosylated haemoglobin [HbA1c] >9%) and severe diabetes or 
hypertension-related end organ damage such as proliferative retinopathy and symptomatic 
cardiovascular disease. Patients with previous intolerance of ACE inhibitors or ARBs, and 
secondary hypertension including renal artery stenosis were also excluded. Where appropriate, 
stable dose of metformin during the 12 weeks before enrolment was required. Patients who were on 
thiazolidinediones were not included. Study participants were not on a controlled diet, but were 
asked not to change their dietary habits during participation in this study. 
The study was a carried out in four study centres and was approved by local ethics committees for 
each site. Written informed consent was obtained from all participants. 
 
Study protocol 
The study protocol has been published previously [20]. There was a 2-week open-label placebo run-
in period to improve blood pressure control to the above targets with hydrochlorothiazide and, if 
required, metoprolol or atenolol. Then randomization to telmisartan (40 mg) or ramipril (5 mg) took 
place using a parallel-group, double-blind, double-dummy design. After 3 weeks into the study 
there was forced titration to 80 mg telmisartan or 10 mg ramipril with add-on therapy if blood 
pressure control remained inadequate (SBP ≥160 mmHg and/or DBP ≥95 mmHg), aiming for a 
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target blood pressure <130/80 mmHg. The present study is a post hoc analysis of the TRENDY 
study. 
 
Assessment of blood pressure and biochemical parameters 
Blood pressure was measured by trained study nurses using a semi automatic device (Dinamap Pro 
100, GE Healthcare, Chalfont St. Giles, UK; or Omron HEM 907XL, Omron, Mannheim, 
Germany). Participants were seated for five minutes before the first measurement was performed. 
Three measurements were taken and the average of these measurements is given. 
Adiponectin was determined in plasma by radioimmunoassay utilizing 125I-labeled murine 
adiponectin and a multispecies adiponectin rabbit antiserum by the double antibody/PEG technique. 
(Linco Research, Inc., St. Charles, MO). The limit of sensitivity is 1 ng/mL, whereas the limit of 
linearity for the Human Adiponectin assay is 200 ng/mL. A 1:500 dilution of samples was therefore 
required. Quality controls were supplied by the manufacturer. Intra and inter assay coefficients of 
variation were less than 8% and 7%, respectively. Aldosterone levels were determined in plasma by 
a commercially available radioimmunoassay (Adaltis Italia S.p.A., Bologna, Italy), and plasma 
angiotensin II levels were determined by radioimmunoassay (antiserum kindly provided by Prof. D. 
Ganten, Max Delbrück Zentrum, Berlin, Germany) as previously described [21]. All these analyses 
were performed in the same run from samples that were frozen and stored at -80 °C immediately 
after centrifugation. Other laboratory parameters were measured by standard biochemistry methods 
in local hospital laboratories: glucose, lipids, ALT, AST and creatinine by photometry; CRP and 
HbA1c by turbidimetry. 
 
Statistical analysis 
Normal distribution was tested by Kolmogorov-Smirnov test and visual inspection of Q-Q plots. 
Data not following normal distribution were log transformed. Data were then compared by paired 
and unpaired Student's t-test as appropriate. In correlation analyses, Pearson correlation coefficients 
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are given. Multiple linear regression was used where indicated either will all covariates entered into 
the model or using a stepwise approach with probabilities of F for entry and removal of 0.05 and 
0.10, respectively. In regression models, sex was coded as 1=male and 2=female. Data are given as 
mean ± standard deviation or median [interquartile range] as appropriate in text and tables and 
mean ± standard error in figure 2. A P-value of ≤0.05 (two-sided) was considered significant. 
Statistical analyses have been carried out using SPSS version 15 (SPSS Inc., Chicago, IL, USA) and 
Minitab version 12 (Minitab Inc., State College, PA, USA) software. 
 
Results 
Characteristics of the study cohort 
Eighty-seven participants were included. Baseline characteristics prior to randomization are 
displayed in Table 1. There were no significant differences between patients receiving ramipril 
(n=42) and those receiving telmisartan (n=45). There was a numerical but not statistically 
significant (P=0.064) difference in baseline adiponectin levels between the groups. 
 
Adiponectin and blood pressure at baseline 
We first examined which factors are correlated with adiponectin levels at baseline in the whole 
study cohort (n=87). There were significant correlations between adiponectin levels and age 
(r=0.324, P<0.01), sex (r=0.323, P=<0.01), systolic (r=-0.240, P<0.05) and diastolic (r=-0.227, 
P<0.05) blood pressure, and high-density lipoprotein (HDL) cholesterol levels (r=0.399, P<0.001). 
Body mass index (r=0.001, P=0.99), total (r=-0.008, P=0.94) and low-density lipoprotein (LDL) 
cholesterol levels (r=-0.040, P=0.72), HbA1c (r=-0.087, P=0.74) and C-reactive protein (CRP) 
levels (r=-0.067, P=0.60) were not correlated with adiponectin levels. 
We then entered adiponectin levels together with other potential predictors of blood pressure 
including age, sex, body mass index and 24-hour urinary sodium excretion in a linear regression 
model. Adiponectin levels were the only predictor of systolic blood pressure (β=-0.287, P<0.05) 
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after adjustment for these covariates using a stepwise regression model (Table 2). The relationship 
between adiponectin and blood pressure is illustrated in Figure 1. 
 
Effects of telmisartan and ramipril on blood pressure and adiponectin 
By treatment with ramipril or telmisartan over a period of 9 weeks the whole study group (n=87) 
experienced a reduction in systolic and diastolic blood pressure by 9.9 [95% CI, 7.2 to 12.7] mmHg 
(P<0.001) and 5.2 [95% CI, 3.6 to 6.9] mmHg (P<0.001), respectively, and an increase in 
adiponectin levels by 0.44 [95%CI, 0.05 to 0.84] µg/mL (P<0.05). Adiponectin levels were also 
correlated with systolic and diastolic blood pressure after treatment, and changes in adiponectin 
levels were correlated with changes in blood pressure (Figure 1). In the whole group of patients, 
change in adiponectin levels were correlated with change in systolic an diastolic blood pressure 
even after adjustment for treatment (P<0.01 and P<0.05, respectively). 
As opposed to the ramipril group there was a significant increase in adiponectin levels in patients 
treated with telmisartan (ramipril: increase by 0.17 [95% CI, -0.56 to 0.90] µg/mL, P=0.67; 
telmisartan: increase by 0.68 [95% CI, 0.27 to 1.10] µg/mL, P<0.01) and the difference between the 
groups was significant (P<0.05) (Table 3). Blood pressure reduction in the telmisartan group 
(change in systolic and diastolic blood pressure by 13.5 [95% CI, 10.0 to 17.0)] mmHg and 7.6 
[95% CI, 5.3 to 9.8)] mmHg, each P<0.001) was significantly (P<0.01 for both systolic and 
diastolic blood pressure) greater than in the ramipril group (change in systolic and diastolic blood 
pressure by 6.1 [95% CI, 2.0 to 6.2)] mmHg and 2.7 [95% CI, 0.5 to 5.0)] mmHg; P<0.01 and 
P<0.05, respectively). 
Because of the numerical difference in baseline adiponectin levels between the group assigned to 
ramipril and telmisartan we examined the effect of treatment on adiponectin in three subsets of 
patients with baseline adiponectin levels <7 µg/mL (n=34), ≥7 µg/mL but <10 µg/mL (n=25) and 
≥10 µg/mL (n=28) to exclude that the observed results are due to regression to the mean. Even in 
the group with lowest baseline levels, ramipril did not significantly increase adiponectin levels, 
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whereas in the telmisartan group only patients with the highest baseline levels did not show further 
increase in adiponectin following treatment (Figure 2). Multiple regression analysis with all 
variables forced into the analysis confirmed that change in systolic blood pressure was associated 
with assignment to treatment group (P<0.05) and change in adiponectin levels throughout the 
treatment period (P<0.01), whereas tertile of basal adiponectin (P=0.91), age (P=0.72), body mass 
index (P=0.89) and sex (P=0.73) were not related to change in systolic blood pressure in this model 
(adjusted R²=12.3%). Similar results have been obtained using a stepwise regression model 
(variables included in the stepwise model: treatment group [P<0.05] and change in adiponectin 
levels [P<0.01]; variables not included in the stepwise model: tertile of basal adiponectin (P=0.94), 
age (P=0.99), body mass index (P=0.91) and sex (P=0.99); adjusted R²=16.2%). 
Associations of treatment with other biochemical parameters are displayed in Table 3. There were 
no differences between the ramipril and telmisartan group on parameters other than adiponectin and 
plasma angiotensin II levels. None of the factors were correlated with changes in adiponectin in the 
whole study group or in the ramipril or telmisartan groups (all P=n.s; data not shown). 
 
Discussion 
We have demonstrated an inverse relationship between plasma adiponectin levels and blood 
pressure in hypertensive patients with type 2 diabetes. Moreover, changes in adiponectin levels 
were related to reduction in blood pressure following treatment with telmisartan or ramipril. 
Patients treated with telmisartan experienced a significant increase in plasma adiponectin levels and 
a more pronounced reduction in blood pressure compared with patients randomized to ramipril. 
A subset of ARBs including telmisartan, irbesartan and losartan has been shown to increase 
adiponectin release from adipocytes independent of the ARBs' action on AT1-receptors via PPARγ 
stimulation [14]. There is evidence for both transcriptional [15,16] and post-transcriptional 
mechanisms involved [17]. In clinical studies telmisartan has been shown to increase circulating 
adiponectin levels in patients with type 2 diabetes [22,23]. Makita et al. [24] recently translated 
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these findings into clinical routine by demonstrating an association between telmisartan use and 
adiponectin levels in hypertensive outpatients. In the present study we have shown that, in contrast 
to the ACE inhibitor ramipril, the ARB telmisartan increases adiponectin plasma levels within a 9-
week treatment period. The correlation between blood pressure reduction and increase in 
adiponectin levels and the greater blood pressure reduction in patients treated with telmisartan 
compared to those treated with ramipril in our study would be consistent with a role of adiponectin 
in the hypotensive effect of telmisartan. However, in the absence of data on PPARγ stimulation in 
the present study further studies are needed to examine this in more detail. 
By employing strict inclusion criteria such as a washout period prior to randomization and limiting 
concomitant hypoglycaemic drugs to metformin together with a relatively large sample size, we 
were able to demonstrate relationships between adiponectin and blood pressure both at baseline and 
following treatment. Our study cannot be directly compared with a previous study by Usui et al. 
[25] who also examined metabolic effect of telmisartan in patients with type 2 diabetes and 
hypertension. In this study [25] telmisartan was administered on top of pre-existing therapy and 
there were no changes in adiponectin levels during a 6-month treatment period. Similarly, Benndorf 
et al. [26] did not find changes in serum adiponectin levels after 6 weeks of treatment with 
telmisartan in nondiabetic patients with essential hypertension although telmisartan improved 
insulin sensitivity. We believe that our present study cohort due to having both conditions, 
hypertension and type 2 diabetes, is particularly suited to examine the effects of telmisartan on 
adiponectin levels and blood pressure. Indeed, adiponectin has been demonstrated to have positive 
effects on insulin sensitivity, inflammation, and atherosclerosis, and insulin-resistance is a feature 
of essential hypertension [27]. Circulating adiponectin levels have been found to be inversely 
correlated with insulin resistance in patients with the metabolic syndrome [28], and the ARB 
candesartan has indeed been found to improve insulin sensitivity [29]. 
The relationship between adiponectin and blood pressure has been previously described in clinical 
studies [9,10,13] but has not been uniformly confirmed in other study cohorts [30]. It is an 
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important feature of our study that we were able to show a relationship between changes in 
adiponectin levels and changes in blood pressure, although this relationship is not necessarily a 
causal one. Our data are indeed in line with a report by Negro et al. [31] who found a relationship 
between amelioration of metabolic parameters including adiponectin and blood pressure reduction 
in obese, insulin resistant, hypertensive patients. The finding that changes in adiponectin levels did 
not correlate with changes in angiotensin II concentration supports an AT1-receptor independent 
stimulation of adiponectin by telmisartan. Our present study, however, does not explain the 
mechanisms linking adiponectin with blood pressure. Amongst the potential mechanisms 
improvement of endothelial function by stimulating endothelial nitric oxide release is an attractive 
hypothesis [13]. We have previously reported improvement of basal nitric oxide activity in the renal 
vasculature of patients in the present study [20], but the absence of a significant difference in 
improvement of renal endothelial function between patients on telmisartan and those on ramipril 
contradicts a direct effect of adiponectin on endothelial function in our patient cohort. Despite 
evidence from experimental models [5] a recent clinical study by Singhal et al. [32] also failed to 
show a relationship between endothelial function and adiponectin levels. Another possible 
mechanism involves induction of body visceral fat remodelling by telmisartan [33] which could 
affect adiponectin production. We could not observe differences in the effect of telmisartan and 
ramipril on liver enzymes, but have not specifically examined changes in visceral fat content and 
distribution in our study. We appreciate that the study period was too short in order to examine all 
metabolic effects in detail. Lastly, it is possible that all blood pressure-lowering effects especially of 
telmisartan are due to direct interaction with the renin-angiotensin-aldosterone system and that any 
effect on PPARγ are not directly related to the antihypertensive effects. 
Our present study has a number of limitations that should be mentioned. First, the study was 
originally designed to examine the effect of telmisartan compared to ramipril on renal 
haemodynamics in patients with type 2 diabetes and hypertension [20], but not specifically designed 
and powered to examine the relationship between adiponectin and blood pressure. The sample size 
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was adequate for the primary aim, but may have been too small for the present analysis. Also, data 
on insulin sensitivity may be useful in interpreting the present findings, but such data have not been 
collected. This may be particularly important given the sexual dimorphism of adiponectin levels as 
also observed in our present study. We could not analyze if the study medication affects adiponectin 
equally in males and females. Secondly, we acknowledge that differential effects of telmisartan and 
ramipril on blood pressure may simply be due to different potency of these drugs on the renin-
angiotensin-aldosterone system. Nevertheless, the differential effect on adiponectin levels between 
telmisartan and ramipril, which may be related to the differential effect on blood pressure, is at least 
intriguing and supports the notion that stimulation of adiponectin contributes to the hypotensive 
effect of telmisartan. Thirdly, adiponectin levels were numerically but not significantly higher in the 
ramipril group at baseline. Our additional analyses in tertiles of baseline adiponectin levels are 
evidence against the possibility that the differential effects of telmisartan and ramipril on 
adiponectin levels are merely due to regression to the mean. Fourthly, although our study includes 
therapeutic intervention and longitudinal data, we acknowledge that we can show a correlation but 
cannot prove a causal relationship between adiponectin and blood pressure. Even in case of 
causality the effect of adiponectin on blood pressure would be moderate as indicated by the modest 
correlation coefficients and R² values. Finally, compared to thiazolidinediones, telmisartan is a 
relatively weak PPARγ activator. Indeed, in the face of similar effects of telmisartan and ramipril on 
cardiovascular outcome [34], PPARγ-related effects of telmisartan may not play an immediate role 
in the majority of patients. Indeed, already in the study by Derosa et al. [23], blood pressure 
reduction was similar in patients treated with telmisartan or irbesartan despite the more pronounced 
increase in adiponectin in the telmisartan group. 
In summary, we have shown that telmisartan was associated with stimulation of adiponectin in 
hypertensive patients with type 2 diabetes. This could contribute to its blood pressure-lowering 
effect. It should be tested whether increasing adiponectin levels particularly in patients with low 
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adiponectin levels offers additional therapeutic benefits. In this scenario telmisartan may be 
superior to other agents including ramipril.  
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Figure Legends 
 
Figure 1. Adiponectin and blood pressure. 
Scatterplots of systolic (SBP) and diastolic blood pressure (DBP) vs logarithm of adiponectin levels 
at baseline (A, B) and after treatment with ramipril or telmisartan (C, D). E and F disply changes in 
blood pressure due to therapy vs changes in adiponectin levels. Subjects randomized to ramipril are 
indicated by open symbols, subjects randomized to telmisartan by solid symbols. Person's 
correlation coefficients (r) are given.  
 
Figure 2. Effects of telmisartan and ramipril on adiponectin levels. 
Changes in plasma adiponectin levels in response to 9 weeks of treatment with ramipril (open bars) 
or telmisartan (solid bars) in the whole study group and in subgroups according to baseline 
adiponectin levels are displayed. Cut-off values of adiponectin for the definition of subgroups 
derived from classification in tertiles with minor adjustments to ensure similar numbers of patients 
allocated to telmisartan and ramipril in each subgroup. Significant changes in adiponectin levels in 
treatment groups are indicated by symbols on top of the bars (* P<0.05; † P<0.01; ‡ P<0.001). Note 
that only in the telmisartan group changes in adiponectin levels were significant. When all patients 
were considered, effects on adiponectin were significantly different between treatment groups 
(P<0.05). Data are given as mean ± standard error. 
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Table 1. Baseline Characteristics. 
 
 
 All Participants Telmisartan Ramipril  
 n=87 n=45 n=42 P-value 
Age (years) 59.2±8.9 59.7±8.7 58.8±9.2 0.64 
Male (%) 69 64 74 0.37 
Height (cm) 172±9 172±9 173±8 0.78 
Weight (kg) 89±17 87±17 91±18 0.23 
Body mass index (kg/m²) 30.0±5.3 29.4±5.3 30.6±5.2 0.28 
Active smokers (%) 18 20 17 0.79 
Duration of diabetes (years) 5 [3;7] 5 [3;9] 5 [3,7] 0.30 
Duration of hypertension (years) 11 [6;16] 12 [6;15] 9 [5;22] 0.69 
Systolic blood pressure (mmHg) 147±12 149±13 146±11 0.20 
Diastolic blood pressure (mmHg) 83±10 84±10 83±9 0.52 
HbA1c (%) 6.8±1.0 7.0±1.1 6.6±0.7 0.13 
Blood glucose (mg/dL) 168 [130;209] 176 [124;219] 167 [135;197] 0.60 
Creatinine (mg/dL) 0.82±0.17 0.81±0.16 0.83±0.18 0.45 
Total cholesterol (mg/dL) 215±43 212±43 219±44 0.47 
LDL cholesterol (mg/dL) 134±34 134±35 135±34 0.96 
HDL cholesterol (mg/dL) 45 [38;53] 47 [38;53] 45 [40;54] 0.85 
Triglycerides (mg/dL) 184 [137;263] 170 [142;257] 201 [123;280] 0.71 
ALT (U/L) 33 [24;48] 32 [24;39] 37 [26;52] 0.29 
AST (U/L) 26 [21;32] 25 [21;30] 26 [19;33] 0.97 
CRP (mg/L) 1.9 [0.9;4.0] 1.6 [0.8;4.0] 2.7 [1.3;4.4] 0.32 
Plasma adiponectin (µg/mL) 8.1 [5.9;11.4] 7.3 [5.0;10.5] 8.5 [6.3;13.0] 0.064 
Plasma angiotensin II (pg/mL) 3.4 [2.3;5.9] 3.5 [2.1;5.5] 3.4 [2.3;6.1] 0.86 
Plasma aldosterone (pg/mL) 128 [107;163] 122 [104;156] 129 [108;167] 0.56 
Urinary sodium excretion (mmol/d) 104±33 102±32 106±33 0.54 
 
 
HbA1c, glycosylated haemoglobin; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
ALT, alanine amino transferase; AST, aspartate amino transferase; CRP, C-reactive protein. Blood 
glucose concentration has been measured 1 to 2 hours after a light breakfast. 
Data are given as mean±standard deviation or median [interquartile range] as appropriate. P-values 
refer to comparisons between the ramipril and telmisartan group and derive from Student's t-test, 
Mann-Whitney U-test and Fisher's exact test for normally distributed, non-normally distributed and 
categorical data, respectively. 
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Table 2. Systolic blood pressure and adiponectin at baseline 
 
 
 All variables entered Stepwise approach 
 B β P-value B β P-value 
Constant 150.08 [122.43 to 177.72] - <0.001 152.62 [146.93 to 158.32] - <0.001 
Sex (1=male, 2=female) -1.17 [-7.45 to 5.16] -0.05 0.71 - - - 
Age (years) -0.02 [-0.33 to 0.30] -0.01 0.91 - - - 
Body mass index (kg/m²) 0.08 [-0.47 to 0.62] 0.03 0.78 - - - 
Adiponectin (µg/mL) -0.54 [-1.19 to 0.10] -0.21 0.098 -0.63 [-1.20 to -0.06] -0.24 <0.05 
24-hour urinary sodium (mmol/d) 0.02 [-0.64 to 0.11] 0.06 0.63 - - - 
 
 
Multiple stepwise regression analysis of the predictive value of sex, age, body mass index, baseline adiponectin levels and 24-hour urinary sodium 
excretion on baseline systolic blood pressure. A model with all variables forced in (adjusted R²=0.1%) and a stepwise approach with probabilities of 
F for entry and removal of 0.05 and 0.10, respectively (adjusted R²=4.4%), was applied. B denotes unstandardized and β denotes standardized 
regression coefficients, respectively. 95% confidence intervals are given for B-values. 
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Table 3. Associations of treatment with other biochemical parameters. 
 
 
 Telmisartan Ramipril  
 n=45 n=42 P-value 
SBP (mmHg) -13.5 [-17.0 to -10.0] -6.1 [-6.2 to -2.0] <0.01 
DBP (mmHg) -7.6 [-9.8 to -5.3] -2.7 [-5.0 to -0.5] <0.05 
Body mass index (kg/m²) -0.3 [-0.5 to 0.0] +0.1 [-0.1 to 0.3] 0.52 
HbA1c (%) -0.08 [-0.24 to 0.08] +0.02 [-0.12 to 0.17] 0.32 
Blood glucose (mg/dL) -5.9 [-18.5 to 6.8] +6.0 [-9.0 to 20.1] 0.22 
Creatinine (mg/dL) +0.03 [0.00 to 0.06] * +0.02 [-0.01 to 0.06] 0.60 
Sodium (mmol/L) -0.21 [-1.09 to 0.67] +0.07 [-0.83 to 0.96] 0.65 
Potassium (mmol/L) +0.07 [-0.18 to 0.31] +0.05 [-0.06 to 0.16] 0.91 
Total cholesterol (mg/dL) +4.3 [-8.9 to 17.5] +0.8 [-9.4 to 11.0] 0.68 
LDL cholesterol (mg/dL) +6.6 [0.9 to 12.3] * +4.1 [-3.0 to 11.2] 0.58 
HDL cholesterol (mg/dL) -1.1 [-3.1 to 1.0] -0.7 [-2.9 to 1.4] 0.82 
Triglycerides (mg/dL) +26.1 [-39.5 to 91.7] -5.6 [-33.1 to 21.9] 0.74 
ALT (U/L) -1.5 [-5.0 to 1.9] -2.9 [-9.0 to 3.2] 0.23 
AST (U/L) -1.8 [-4.1 to 0.5] -2.1 [-4.6 to 0.3] 0.56 
CRP (mg/L) +1.0 [-0.9 to 2.8] -0.3 [-0.9 to 0.4] 0.66 
Plasma adiponectin (µg/mL) +0.7 [0.3 to 1.1] ‡ +0.2 [-0.6 to 0.9] <0.05 
Plasma angiotensin II (pg/mL) +6.8 [2.6 to 10.9] ‡ -1.6 [-3.3 to 0.2] <0.001 
Plasma aldosterone (pg/mL) -18.4 [-30.0 to -7.1] † -22.5 [-40.1 to -5.0] ‡ 0.37 
Urinary sodium excretion (mmol/d) -7.6 [-16.6 to 1.3] +2.6 [-7.9 to 13.6] 0.14 
Urinary potassium excretion (mmol/d) -1.29 [-5.45 to 2.87] -1.28 [-5.24 to 2.68] 1.00 
 
 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycosylated haemoglobin; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; ALT, alanine amino transferase; 
AST, aspartate amino transferase; CRP, C-reactive protein. Blood glucose concentration has been 
measured 1 to 2 hours after a light breakfast. 
Data are given as mean [95% confidence interval] irrespective of the distribution of variables to 
facilitate interpretation of data. P-values in the right column refer to comparisons between the 
ramipril and telmisartan group and derive from Student's t-test or Mann-Whitney U-test as 
appropriate. Within groups, asterisks (*; P<0.05), daggers (†; P<0.01) and double daggers (‡; 
P<0.001) denote significant differences in a parameter; these comparisons have been made by 
paired Student's t-test on native data or on data after log transformation in case of non-normal 
distribution. 
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